BGI Genomics
Guanglei Li is a Senior Project Manager at Beijing Genomics Institute in Shenzhen since May 2014, previously serving as a Senior Scientist and leader of the Transporter and Permeability groups at WuXi AppTec from August 2013 to May 2014. Guanglei's expertise includes managing drug metabolism and pharmacokinetics studies, designing in vitro transport studies, and supervising junior scientists. A postdoctoral research scientist at the University of Southern California from 2010 to 2013, Guanglei focused on studying trans-membrane protein Claudin-18's role in pulmonary transport and barrier functions. Academic training includes a Ph.D. in Biomedical Engineering from the City University of New York, supplemented by a master's in Mechanical Engineering from Louisiana State University. Early research experience at the City College of New York involved developing in vitro blood-brain barrier models and investigating drug transport mechanisms.
This person is not in the org chart
This person is not in any offices
BGI Genomics
3 followers
BGI was founded in 1999 as a research organization to support the Human Genome Project. Over the years, BGI’s in-house research has contributed to the development of the field of Genomics in significant ways, as evidenced by a wealth of peer-reviewed publications in prestigious scientific journals. Today, BGI is actively participating in the fields of Cancer Research, Bio-sustainability and Personalized Medicine through a global network of collaborators. BGI Genomics is the world’s leading provider of genomic and proteomic services, now serving customers in more than 66 countries. We provide academic institutions, pharmaceutical companies, health care providers and other organizations with integrated genomic and proteomic services and solutions across a broad range of applications spanning basic and translational research, drug discovery, agriculture and health care. To provide these services, we operate a large network of service Laboratories in China, Hong Kong, the US and Europe. Our customers benefit from the highest level of sequencing experience in the world to support their research and drug discovery projects. Our service laboratories operate under strict internationally recognized quality systems, such as those from CAP and ISO. More recently, BGI developed and launched its own DNBseq™ sequencing technology, based on DNA Nanoball sequencing technology that was invented in our Complete Genomics research facility in Silicon Valley, California. Scientists around the world now rely on DNBseq NGS services for the highest quality data at the lowest cost.